Abstract
Objective To determine how the severity of successively dominant SARS-CoV-2 variants changed over the course of the COVID-19 pandemic.
Design Retrospective cohort analysis.
Setting Community- and hospital-sequenced COVID-19 cases in the NHS Greater Glasgow and Clyde (NHS GG&C) Health Board.
Participants All sequenced non-nosocomial adult COVID-19 cases in NHS GG&C infected with the relevant SARS-CoV-2 lineages during analysis periods. B.1.177/Alpha: 1st November 2020 - 30th January 2021 (n = 1640). Alpha/Delta: 1st April - 30th June 2021 (n = 5552). AY.4.2 Delta/non-AY.4.2 Delta: 1st July - 31st October 2021 (n = 9613). Non-AY.4.2 Delta/Omicron: 1st - 31st December 2021 (n = 3858).
Main outcome measures Admission to hospital, ICU, or death within 28 days of positive COVID-19 test
Results For B.1.177/Alpha, 300 of 807 B.1.177 cases were recorded as hospitalised or worse, compared to 232 of 833 Alpha cases. After adjustment, the cumulative odds ratio was 1.51 (95% CI: 1.08-2.11) for Alpha versus B.1.177. For Alpha/Delta, 113 of 2104 Alpha cases were recorded as hospitalised or worse, compared to 230 of 3448 Delta cases. After adjustment, the cumulative odds ratio was 2.09 (95% CI: 1.42-3.08) for Delta versus Alpha. For non-AY.4.2 Delta/AY.4.2 Delta, 845 of 8644 non-AY.4.2 Delta cases were recorded as hospitalised or worse, compared to 101 of 969 AY.4.2 Delta cases. After adjustment, the cumulative odds ratio was 0.99 (95% CI: 0.76-1.27) for AY.4.2 Delta versus non-AY.4.2 Delta. For non-AY.4.2 Delta/Omicron, 30 of 1164 non-AY.4.2 Delta cases were recorded as hospitalised or worse, compared to 26 of 2694 Omicron cases. After adjustment, the median cumulative odds ratio was 0.49 (95% CI: 0.22-1.06) for Omicron versus non-AY.4.2 Delta.
Conclusions The direction of change in disease severity between successively emerging SARS-CoV-2 variants of concern was inconsistent. This heterogeneity demonstrates that severity associated with future SARS-CoV-2 variants is unpredictable.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. Funding was also provided by UKRI through the JUNIPER consortium (grant number MR/V038613/1). Sequencing and bioinformatics support at the CVR was funded by the Medical Research Council (MRC) core award (MC UU 12014/12). We acknowledge the support of the G2P-UK National Virology Consortium (MR/W005611/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Anonymised clinical data were available using the NHS Greater Glasgow and Clyde (NHS GG&C) SafeHaven platform and included vaccination status (dates and product names for each dose), demographic data (age, sex and Scottish Index of Multiple Deprivation (SIMD) quartile) comorbidity (shielding and immunosuppression status) and dates of positive and negative PCR tests, for 1.2 million inhabitants of the (NHS GG&C) area over 18 years of age. Data were matched by CHI number and pseudonymised before analysis. Derogated ethical approval for the study was granted by the NHS GG&C SafeHaven committee (GSH/21/IM/001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
david.pascall{at}mrc-bsu.cam.ac.uk
Elen.Vink{at}glasgow.ac.uk
Rachel.Blacow{at}ggc.scot.nhs.uk
naomi.bulteel2{at}nhs.scot
alasdair.campbell5{at}nhslothian.scot.nhs.uk
robyn.campbell{at}nhslothian.scot.nhs.uk
sarah.clifford{at}nhslothian.scot.nhs.uk
chris.davis{at}glasgow.ac.uk
ana.dasilvafilipe{at}glasgow.ac.uk
noha.elsakka{at}nhs.scot
Ludmila.Fjodorova2{at}nhs.scot
ruth.forrest2{at}nhs.scot
Emily.Goldstein{at}ggc.scot.nhs.uk
Rory.Gunson{at}ggc.scot.nhs.uk
John.Haughney{at}ggc.scot.nhs.uk
matt.holden{at}nhs.scot
patrick.honour3{at}borders.scot.nhs.uk
joseph.hughes{at}glasgow.ac.uk
edward.james{at}borders.scot.nhs.uk
timothy.lewis{at}nhslothian.scot.nhs.uk
Oscar.MacLean{at}glasgow.ac.uk
martin.mchugh{at}nhslothian.scot.nhs.uk
Guy.Mollett{at}ggc.scot.nhs.uk
tommy.nyberg{at}mrc-bsu.cam.ac.uk
yusuke.onishi{at}nhs.scot
b.j.parcell{at}dundee.ac.uk
surajit.ray{at}glasgow.ac.uk
david.l.robertson{at}glasgow.ac.uk
shaun.seaman{at}mrc-bsu.cam.ac.uk
Sharif.Shaaban2{at}phs.scot
James.Shepherd.2{at}glasgow.ac.uk
katherine.smollett{at}glasgow.ac.uk
Kate.Templeton{at}nhslothian.scot.nhs.uk
elizabeth.wastnedge{at}nhslothian.scot.nhs.uk
Craig.Wilkie{at}glasgow.ac.uk
thomaschristiewilliams{at}gmail.com
Updated to be consistent with submitted version. Change in author order. Shortening of abstract consistent with journal requirements.
Data Availability
Raw data is personally identifiable, and so are not available, but aggregated data are provided in the supplementary materials.